Favipiravir will be used for coronavirus treatment after registration in Kazakhstan, said Dinagul Bayesheva, leading infectiologist.
Favipiravir is a drug that was developed in Japan and is currently undergoing clinical trials, and we are also interested in it. After registering this drug, we will have the opportunity to conduct clinical tests in our country," she said.
She previously reported that not all patients are prescribed hydroxychloroquine, which has been abandoned in a number of developed countries.
As reporter before, China has completed the clinical research of Favipiravir, an antiviral drug that has shown good clinical efficacy against the novel coronavirus disease (COVID-19).
This information may not be reproduced without reference to Kazakhstan Today. Copyright of materials of News Agency Kazakhstan Today.
When citing our content a hyperlink to this Kazakhstan Today website is obligatory.